
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2347524/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	9.0	272
2	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
3	MRI characteristics and scoring in HDLS due to <i>CSF1R</i> gene mutations. Neurology, 2012, 79, 566-574.	1.1	153
4	Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism and Related Disorders, 2014, 20, 957-964.	2.2	140
5	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism and Related Disorders, 2013, 19, 869-877.	2.2	119
6	Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 168-173.	1.9	106
7	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain, 2014, 137, 1533-1549.	7.6	100
8	Update on novel familial forms of Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2014, 20, S29-S34.	2.2	84
9	Clobal Survey on Telemedicine Utilization for Movement Disorders During the <scp>COVID</scp> â€19 Pandemic. Movement Disorders, 2020, 35, 1701-1711.	3.9	73
10	Autosomal dominant cerebellar ataxia type I: A review of the phenotypic and genotypic characteristics. Orphanet Journal of Rare Diseases, 2011, 6, 33.	2.7	68
11	Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathologica, 2015, 129, 53-64.	7.7	67
12	TARDBP mutations in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 312-315.	2.2	49
13	<i>LRRK2</i> exonic variants and risk of multiple system atrophy. Neurology, 2014, 83, 2256-2261.	1.1	46
14	Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism and Related Disorders, 2015, 21, 101-105.	2.2	42
15	Cancer in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 31, 28-33.	2.2	41
16	Analysis of COQ2gene in multiple system atrophy. Molecular Neurodegeneration, 2014, 9, 44.	10.8	40
17	Establishing diagnostic criteria for Perry syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 482-487.	1.9	40
18	Autosomal dominant Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, S7-S10.	2.2	39

#	Article	IF	CITATIONS
19	A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathologica, 2015, 130, 199-214.	7.7	38
20	Partial but Rapid Recovery from Paralysis after Immunomodulation during Early Stage of Neuralgic Amyotrophy. European Neurology, 2006, 55, 227-229.	1.4	35
21	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. Neurology, 2013, 80, 2076-2078.	1.1	31
22	Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
23	The Prevalence of Constipation and Irritable Bowel Syndrome in Parkinson's Disease Patients According to Rome III Diagnostic Criteria. Journal of Parkinson's Disease, 2017, 7, 353-357.	2.8	31
24	Progressive Supranuclear Palsy: High-Field-Strength MR Microscopy in the Human Substantia Nigra and Globus Pallidus. Radiology, 2013, 266, 280-288.	7.3	26
25	Occurrence of Crohn's disease with Parkinson's disease. Parkinsonism and Related Disorders, 2017, 37, 116-117.	2.2	26
26	Mutations in bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome. Scientific Reports, 2018, 8, 819.	3.3	26
27	Clinicopathologic variability of the <i>CRN</i> A9D mutation, including amyotrophic lateral sclerosis. Neurology, 2013, 80, 1771-1777.	1.1	24
28	Three families with Perry syndrome from distinct parts of the world. Parkinsonism and Related Disorders, 2014, 20, 884-888.	2.2	24
29	Hospital-based study on emergency admission of patients with Parkinson's disease. ENeurologicalSci, 2016, 4, 19-21.	1.3	24
30	The impact of early morning off in Parkinson's disease on patient quality of life and caregiver burden. Journal of the Neurological Sciences, 2016, 364, 1-5.	0.6	24
31	Update on Genetics of Parkinsonism. Neurodegenerative Diseases, 2012, 10, 257-260.	1.4	23
32	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	2.2	23
33	An adult-onset leukoencephalopathy with axonal spheroids and pigmented glia accompanied by brain calcifications. Journal of Neurology, 2013, 260, 2665-2668.	3.6	22
34	Sequence variants in eukaryotic translation initiation factor 4-gamma (elF4G1) are associated with Lewy body dementia. Acta Neuropathologica, 2013, 125, 425-438.	7.7	20
35	The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study. Internal Medicine, 2017, 56, 1961-1966.	0.7	19
36	DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation. International Journal of Molecular Sciences, 2021, 22, 3985.	4.1	19

#	Article	IF	CITATIONS
37	Diffusion-weighted MRI in familial Creutzfeldt–Jakob disease with the codon 200 mutation in the prion protein gene. Journal of the Neurological Sciences, 2005, 232, 45-49.	0.6	18
38	An International Survey of Deep Brain Stimulation Utilization in Asia and Oceania: The DBS Think Tank East. Frontiers in Human Neuroscience, 2020, 14, 162.	2.0	18
39	Clinical Aspects of Familial Forms of Frontotemporal Dementia Associated with Parkinsonism. Journal of Molecular Neuroscience, 2011, 45, 359-365.	2.3	17
40	Tremor in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 27, 93-97.	2.2	17
41	Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Frontiers in Microbiology, 2019, 10, 2110.	3.5	17
42	Impact of motor and nonmotor symptoms in Parkinson disease for the quality of life: The Japanese Quality-of-Life Survey of Parkinson Disease (JAQPAD) study. Journal of the Neurological Sciences, 2020, 419, 117172.	0.6	17
43	Multiple system atrophy and apolipoprotein E. Movement Disorders, 2018, 33, 647-650.	3.9	15
44	Familial Progressive Supranuclear Palsy: A Literature Review. Neurodegenerative Diseases, 2014, 13, 180-182.	1.4	14
45	Perry Disease: Concept of a New Disease and Clinical Diagnostic Criteria. Journal of Movement Disorders, 2021, 14, 1-9.	1.3	13
46	Impulse control disorders and punding in Perry syndrome. Parkinsonism and Related Disorders, 2015, 21, 1381-1382.	2.2	12
47	Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome associated with bilateral pleural and pericardial effusions: a case report. Journal of Medical Case Reports, 2016, 10, 198.	0.8	12
48	Dysphagia in Multiple System Atrophy of Cerebellar and Parkinsonian Types. Journal of Neurology and Neuroscience, 2017, 08, .	0.4	12
49	A case of encephalitis lethargica associated with relapsing polychondritis. Movement Disorders, 2008, 23, 2421-2423.	3.9	11
50	Caffeine and Parkinson disease. Neurology, 2018, 90, 205-206.	1.1	11
51	Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells. International Journal of Molecular Sciences, 2018, 19, 3870.	4.1	10
52	Sensitivity and specificity of cardiac 123I-MIBG scintigraphy for diagnosis of early-phase Parkinson's disease. Journal of the Neurological Sciences, 2019, 407, 116409.	0.6	10
53	Biofeedback Core Exercise Using Hybrid Assistive Limb for Physical Frailty Patients With or Without Parkinson's Disease. Frontiers in Neurology, 2020, 11, 215.	2.4	10
54	Association study between multiple system atrophy and TREM2 p.R47H. Neurology: Genetics, 2018, 4, e257.	1.9	9

#	Article	IF	CITATIONS
55	Surgical management of adverse events associated with deep brain stimulation: A single-center experience. SAGE Open Medicine, 2020, 8, 205031212091345.	1.8	9
56	Acute motor sensory axonal neuropathy associated with Henoch-Schönlein purpura. Journal of the Neurological Sciences, 2007, 263, 169-173.	0.6	8
57	The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study. BMC Neurology, 2021, 21, 242.	1.8	8
58	Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study. BMC Neurology, 2015, 15, 105.	1.8	7
59	Characteristics of tongue and pharyngeal pressure in patients with neuromuscular diseases. Degenerative Neurological and Neuromuscular Disease, 2017, Volume 7, 71-78.	1.3	7
60	Relationship between tongue pressure and functional oral intake scale diet type in patients with neurological and neuromuscular disorders. Clinical Neurology and Neurosurgery, 2020, 198, 106196.	1.4	7
61	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	2.2	6
62	Serum uric acid level is linked to the disease progression rate in male patients with multiple system atrophy. Clinical Neurology and Neurosurgery, 2017, 158, 15-19.	1.4	6
63	Behavioral profile in a Dctn1G71A knock-in mouse model of Perry disease. Neuroscience Letters, 2021, 764, 136234.	2.1	6
64	Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease. Expert Opinion on Drug Safety, 2022, 21, 137-147.	2.4	6
65	Clinical presentation of a patient with SLC20A2 and THAP1 deletions: Differential diagnosis of oromandibular dystonia. Parkinsonism and Related Disorders, 2015, 21, 329-331.	2.2	5
66	Meta-iodobenzylguanidine myocardial scintigraphy in Perry disease. Parkinsonism and Related Disorders, 2021, 83, 49-53.	2.2	5
67	Personalized Medicine in Parkinson's Disease: New Options for Advanced Treatments. Journal of Personalized Medicine, 2021, 11, 650.	2.5	5
68	Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients. ENeurologicalSci, 2021, 25, 100369.	1.3	5
69	Longstanding IgG4-related Ophthalmic Disease Dramatically Improved after Steroid Therapy. Internal Medicine, 2018, 57, 2879-2883.	0.7	4
70	A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma. Medicine (United States), 2021, 100, e27450.	1.0	4
71	PLA2G6-associated neurodegeneration in four different populations-case series and literature review. Parkinsonism and Related Disorders, 2022, 101, 66-74.	2.2	4
72	A novel de novo pathogenic mutation in theCACNA1Agene. Movement Disorders, 2012, 27, 1578-1579.	3.9	3

5

#	Article	IF	CITATIONS
73	<i>DCTN1</i> Mutations and Progressive Supranuclear Palsy–Like Phenotype. JAMA Neurology, 2014, 71, 655.	9.0	3
74	Impact of Progression of Parkinson's Disease on Swallowing Ability and Oral Environment. Parkinson's Disease, 2021, 2021, 1-6.	1.1	3
75	A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. Journal of the Neurological Sciences, 2021, 423, 117366.	0.6	3
76	Longitudinal Changes of Tongue Thickness and Tongue Pressure in Neuromuscular Disorders. BMC Neurology, 2021, 21, 302.	1.8	3
77	Off Time Independently Affects Quality of Life in Advanced Parkinson's Disease (APD) Patients but Not in Non-APD Patients: Results from the Self-Reported Japanese Quality-of-Life Survey of Parkinson's Disease (JAQPAD) Study. Parkinson's Disease, 2021, 2021, 1-9.	1.1	3
78	Evaluation of Motor Complications in Parkinson's Disease: Understanding the Perception Gap between Patients and Physicians. Parkinson's Disease, 2021, 2021, 1-8.	1.1	3
79	A case of sudden deterioration in Parkinson disease. Neurology, 2016, 87, 1422-1422.	1.1	2
80	Dysphagia in Perry Syndrome: Pharyngeal Pressure in Two Cases. Case Reports in Neurology, 2017, 9, 161-167.	0.7	2
81	Acute cholecystitis induced by surgery for levodopa-carbidopa intestinalÂgel therapy: Possible relationship to pre-existing gallstones. Parkinsonism and Related Disorders, 2018, 54, 107-109.	2.2	2
82	Perry disease: recent advances and perspectives. Expert Opinion on Orphan Drugs, 2019, 7, 253-259.	0.8	2
83	Hypertrophic pachymeningitis associated with Sjögren's syndrome: case report and literature review. Neurologia I Neurochirurgia Polska, 2022, 56, 195-196.	1.2	2
84	Physical Activity and Its Diurnal Fluctuations Vary by Non-Motor Symptoms in Patients with Parkinson's Disease: An Exploratory Study. Healthcare (Switzerland), 2022, 10, 749.	2.0	2
85	Impulsive and compulsive parkin disease. Neurology, 2016, 87, 1426-1427.	1.1	1
86	Does cigarette smoking do nothing but harm?. Neurology, 2018, 90, 307-308.	1.1	1
87	A novel promising therapeutic approach for patients with ataxic disorders?. Neurology, 2018, 91, 541-542.	1.1	1
88	How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists. Clinical Neurology and Neurosurgery, 2020, 199, 106266.	1.4	1
89	VI. Emergency and Perioperative Management of the Parkinson's Disease Patients. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1578-1584.	0.0	0
90	Radiofrequency Ventro-oral Thalamotomy for Post-stroke Focal Dystonia in a Pediatric Patient. NMC Case Report Journal, 2021, 8, 445-450.	0.5	0

#	Article	IF	CITATIONS
91	Fluctuating pain in Parkinson's disease: Its prevalence and impact on quality of life. ENeurologicalSci, 2021, 25, 100371.	1.3	0